Briacell Therap (NASDAQ:BCTX) Downgraded to “Strong Sell” Rating by Wall Street Zen
by Amy Steele · The Cerbat GemWall Street Zen lowered shares of Briacell Therap (NASDAQ:BCTX – Free Report) from a sell rating to a strong sell rating in a research report report published on Saturday.
Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Briacell Therap in a report on Wednesday, January 21st. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $320.00.
Check Out Our Latest Stock Report on BCTX
Briacell Therap Stock Down 5.7%
BCTX stock opened at $4.28 on Friday. The firm has a market cap of $31.03 million, a price-to-earnings ratio of -0.18 and a beta of 1.30. Briacell Therap has a 12-month low of $3.60 and a 12-month high of $98.20. The company’s fifty day simple moving average is $4.13 and its 200 day simple moving average is $7.57.
Briacell Therap (NASDAQ:BCTX – Get Free Report) last released its earnings results on Tuesday, March 10th. The company reported ($2.58) earnings per share (EPS) for the quarter. Research analysts expect that Briacell Therap will post -2.45 earnings per share for the current year.
Hedge Funds Weigh In On Briacell Therap
An institutional investor recently bought a new position in Briacell Therap stock. Flagship Harbor Advisors LLC acquired a new stake in shares of Briacell Therap (NASDAQ:BCTX – Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 4,000 shares of the company’s stock, valued at approximately $28,000. Flagship Harbor Advisors LLC owned 0.21% of Briacell Therap at the end of the most recent quarter. Institutional investors and hedge funds own 15.42% of the company’s stock.
Briacell Therap Company Profile
BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers.